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ABSTRACT
RED BLOOD CELL BIOMECHANICS IN MYALGIC
ENCAPHALOMYELITIS/CHRONIC FATIGUE SYNDROME
By Arun Kumar
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterized by
severe fatigue, impaired cognition, and discomfort. Unfortunately, the etiology and
pathogenesis of the disease are not well understood, and there are no diagnostic
biomarkers. Early studies have shown that the red blood cells (RBC) in ME/CFS patients
have poor filterability. This finding has been implicated in impaired microvascular
oxygenation, which may contribute to post exertional malaise and profound fatigue. We
hypothesized that RBC biomechanics in patients with ME/CFS are significantly different
from those in healthy controls. To test this hypothesis, we use a microfluidic device with
microchannels that are narrower than the diameter of a typical RBC. RBCs are forced to
deform as they flow through the constrictions, and we observe their shape transitions,
changes in velocity, and other metrics that collectively can be used to assess cellular
biomechanics. The data suggest that RBC deformability is significantly reduced in
patients with ME/CFS. Further studies are warranted to fully evaluate the potential of
RBC deformability as a biomarker for ME/CFS.
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Chapter 1: Introduction
1.1 Chronic Fatigue Syndrome
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disease that
causes profound fatigue, pain, and mental exhaustion that does not improve with rest. It is
a major disease that affects over 2 million Americans, yet the mechanism of the disease
and its etiology are still poorly understood [1]. The patients are often in a constant state
of discomfort and there are currently no available cures. In a study by Hvidberg et al., a
survey was conducted to assess the health-related quality of life for patients with many
major diseases including CFS, depression, various cancers, and heart problems.
Surprisingly, the results showed that patients suffering from CFS had the lowest quality
of life among the survey’s participants [2].
Unfortunately, there is no quantitative diagnostic test for CFS. The method of
diagnosis currently uses a questionnaire in which a patient must match a description of
symptoms, or diagnostic criteria [3]. As a result, many people do not know they have the
disease and may not have access to treatments for their symptoms or education that may
improve their lives. Understanding the origins of the disease and how they manifest into
symptoms could be the first step in finding a cure.
Early studies on CFS have found a relationship between the disease and oxidative
stress in the immune and hematological systems [4]. Oxidative stress is the result of
damage from free radicals in the body that are created by naturally occurring processes
[5]. The harmful effects from these free radicals are normally suppressed by antioxidants.
However, a deficiency of antioxidants can allow free radicals to damage cells, DNA, and
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proteins. In red blood cells (RBCs), oxidative stress results in decreased deformability
[6]. Based on these findings, we hypothesize that red blood cell deformability is
decreased in patients with CFS. By measuring RBC deformability in patients with CFS,
we can identify a potential biomarker to diagnose CFS quantitatively.
1.2 Measuring RBC Deformability
In patients suffering from CFS, RBCs may be less deformable and have a reduced
ability to supply oxygen to tissues in the body. During an RBC’s lifetime of about 120
days, it must traverse microvasculature where the capillaries may be barely large enough
to accommodate a single cell [7]. Typical RBCs have diameters of 6-8 μm, and the
capillaries can be as small as 3-4 μm in diameter [8]. To effectively perform their
function of traversing tortuous vessels to oxygenate tissues, cells needs to undergo
significant deformation and be able to elastically recover to their original shapes.
RBC deformability is the property that allows RBCs to reversibly change shape to
more easily flow through physical confinement. RBC deformability is already a
quantifiable measurement that is an established biomarker for some diseases, including
sickle cell anemia and malaria [9], [10] . These two conditions are characterized by
decreased RBC deformability and have some symptoms in common with CFS. RBCs are
also known to be less deformable after storage outside the body for prolonged periods of
time [7]. In these three cases, RBC performance is impaired, which is associated with
measurable changes in deformability. It is clear that the biomechanical properties of
RBCs can provide insights into microcirculation and even be a predictor of RBC
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performance. The behavior of RBCs in blood vessels can help shed light on a patient’s
macroscopic physiology and overall health.
There are a few methods commonly used to measure the biomechanics of RBCs.
Atomic force microscopy (AFM) uses a flexible cantilever to apply a force to a cell, and
the deflection of the cantilever is used to calculate the cell’s Young’s modulus (E). For
healthy RBCs in phosphate-buffered saline (PBS), E calculated by AFM is 1.10 ± 0.40
kPa [11]. A force map can then be generated showing the differences in deformability for
specific regions of the cell. It is a highly sensitive method that is time-consuming and
complex, and experimental conditions must be tightly controlled.
Optical tweezers can also be used to measure RBC mechanical properties. This
method uses beads that adhere to the cell and are manipulated with lasers [12]. The beads
are pulled apart to apply precise shearing forces with a high degree of control, and the
RBC deformability can be measured in terms of the shear modulus. The shear modulus of
RBCs in PBS was 6.23 ± 0.33 pN/µm. After being exposed to oxidative stress (200 µM
H2O2), the shear modulus increased approximately two-fold. An optical tweezer system
offers a reliable and accurate measurement technique for RBC deformability. A
disadvantage of this method is that experiments must be done quickly to prevent cells
from taking thermal damage from the lasers.
Another method is micropipet aspiration. A micropipet is a glass tube with a diameter
smaller than that of an RBC. A negative pressure is applied through the tube and the RBC
is drawn into the pipet, where its response to confinement can be used to calculate the
bending elastic modulus [13]. The bending elastic modulus of the membrane (B) was
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found to be 1.8 X 10-12 dyn-cm. Again, it is an accurate but time-consuming method that
only handles single cells at a time.
The above methods are often considered the “gold standards” of measuring RBC
deformability; however, they are all tedious and have a low throughput. In clinical
research where large populations of RBCs are needed from many donors, measuring
deformability with these methods would not be feasible. To address one part of this
problem, ektacytometry can be considered. Ektacytometry uses laser diffraction to
measure the behavior of cells at a fixed shear rate. It is a high throughput method
(thousands of cells) that measures the elastic characteristics of RBCs [14]. While
ektacytometry has this advantage over the above methods, it is far less sensitive, and can
only report mean values of whole cell populations rather than single cell values at high
precision.
1.3 Microfluidic Devices for RBC Biomechanics
To address the drawbacks of the methods described above, we can use a microfluidic
device that is capable of high throughput analysis (hundreds of cells) at single cell
precision. The assembled device will be a polydimethylsiloxane (PDMS) chip with
embedded microstructures bonded to a glass slide. The microstructures are designed to
force cells into a confined region, where their biomechanical behavior is captured using
microscopy and high-speed imaging. To quantify their deformabilities, the videos are
analyzed with image processing software and various parameters can be measured. This
method has some physiological relevance as well, since it mimics the flow of RBCs
through narrow capillaries in vivo.
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Photolithography is a frequently used process in fabricating microfluidic devices. A
design is created using computer-aided design (CAD) software, which is then embossed
onto a silicon substrate using light and photosensitive materials [15]. It is an expensive
and complex process, but it can produce extremely small and intricate patterns which can
be reproduced easily. PDMS is poured onto the silicon mold, where it is crosslinked and
cured with heat. The result is a clear, flexible chip with a void where the embossed
structures indent the material. The PDMS chip and a glass slide are plasma-treated and
bonded together, forming a covalent bond and sealing the hollow microstructures in the
device. The device itself is inexpensive and not difficult to manufacture.
A small sample volume of blood is added to the inlet of the device, and negative
pressure is applied from the outlet. The cells flow through the constrictions and data can
be collected. Using this device allows for rapid experiments for a large number of
patients, making the time required to draw conclusions very short. Preliminary data
collected using this method suggest that RBCs in patients with CFS have reduced
deformability [16]. Studying the deformability of RBCs with this method can be used in
research to search for biomarkers in RBCs, and potentially serve as a standalone clinical
test for CFS.
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Chapter 2: Literature Review
2.1 Microfluidic Device Design
There are several considerations that should be made when designing a device that
needs to effectively and efficiently measure cell deformability. First, it should be
relatively simple to set up so that experimental conditions can remain as static as
possible. Furthermore, parameters such as pressure gradient, pH, and temperature should
be physiologically relevant. And, to test the cell’s ability to deform, it must change shape
with some applied forces. One of the simplest ways to do this is by forcing the cells
through a constriction and observing the effects on them.
A basic design was used to measure deformability by filtering suspensions of RBCs
through 5 µm pores (Figure 1). The RBCs were significantly diluted (1% hematocrit) in
PBS and treated with increasing concentrations of glutaraldehyde (0.01% - 0.6%) [17].
Glutaraldehyde is a crosslinking agent that nonspecifically crosslinks RBC membrane
proteins, causing the cells to maintain rigid, circular shapes. A pressure was applied to
flow the cells across the filter, and the filtering time was measured.
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Figure 1. Filterability of RBCs with glutaraldehyde [17].
The results showed that the filtering time increased with glutaraldehyde
concentration. At a glutaraldehyde concentration of 0.06%, the filtration time began to
increase. At concentrations from 0.1% and up, the cells were stiff enough to completely
block the pores and not pass through. This device provided a convenient way of
measuring the deformability of many cells at once, but this design is not sensitive enough
to provide information on single cells.
To more closely mimic microvasculature, RBCs need to flow through long
constrictions rather than pores. Another study utilized an 18 µm constriction to flow cells
through and measure deformability in a capillary-like setting [18]. The cells were
chemically treated with diamide and glutaraldehyde. Diamide is known to increase the
elastic modulus of RBCs by crosslinking the spectrin network. Data from various
chemical treatments are shown in Figure 2.
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Figure 2. Elongation indices of chemically stiffened cells in constriction. Mean values are
shown with one standard error of the mean [18].
The constricted region of 18 µm width used here is quite large relative to a typical
RBC. However, the flow generated enough shear stress to observe differences in the
untreated and treated cells. Figure 2 shows the ratios of the deformed cell length (L) in
the direction of the flow to the initial undeformed length (Lin). The curve for
glutaraldehyde treated cells is much lower than that of the diamide treatment and the
control group. That means that those cells elongated significantly less than the other two
groups. While it is true that glutaraldehyde has a stronger stiffening effect on cells than
diamide, diamide also affects deformability in a noticeable way. In Figure 3A, a higher
percentage of diamide cells, compared to the other conditions, were observed to “stretch”
in the constriction. This is a distinct morphological effect that is specific to diamide
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treated cells. Similarly, the tumbling motion in Figure 3B is more representative of
glutaraldehyde treated cells.
The cell morphology after a diamide treatment is visually apparent. However, in the
elongation index curves, it closely resembles the untreated cells. A potential reason we do
not see a more pronounced difference between diamide and untreated cells is that the
channel does not offer enough confinement to squeeze the cell. If the constriction was
smaller than the diameter of the cell, the cell would be forced to change shape and stretch
as it contacts the channel walls. This way, a more precise measurement of the stiffness of
the cell could be made. In a disease like CFS where there is a range of severities, even
small differences in biomechanical characteristics could be crucial for diagnostic
purposes. Therefore, it is important to design a microfluidic system that can detect very
slight variations in cell stiffness.
Another interesting finding in this study involved the differences in cell shape
between two concentrations of diamide. In Figure 3A, the cell shown was treated with 38
µM diamide. In Figure 3B, the concentration of diamide used was substantially higher, at
3.8 mM. Elongation index alone may not be enough to measure these differences, based
on the data in Figure 3. By looking at the dramatically different cell morphologies, it is
evident that 2D shape analysis will be a valuable metric.
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Figure 3. Treated RBC length and shape through confinement. (A) 38 µM diamide. (B)
0.05% glutaraldehyde. (C) 3.8 mM [18].
2.2 RBC Deformability as a Biomarker
Poor RBC function can affect entire organ systems and cause serious adverse health
conditions; this decline in performance can often be implicated in abnormal cellular
biomechanics. There are diseases that can physically change properties in RBCs and
cause them to perform less efficiently. If these physical alterations can be measured, they
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may be useful as indicators of the diseases, or biomarkers. Understanding these
mechanisms may shed light on ways to address certain diseases, such as therapeutics or
diagnostics.
Sickle cell disease (SCD) is an inherited rheological disease that causes the body to
produce abnormal crescent-shaped RBCs. The normal biconcave disc shape of an RBC
allows it to fold and bend in response to the dynamic flow patterns within blood vessels.
Sickle cells have been associated with stronger adhesion to vessel walls which leads to
blood flow blockage [19]. This is due to the abnormal polymerization of hemoglobin S
molecules that cause increased RBC stiffness and membrane damage. Alapan et al.
developed a microfluidic based chip that measures deformability and adhesion in patients
with SCD to assess the severity of the disease [19].
The base of the microfluidic channel was cultured with epithelial cells to mimic the
inside of a blood vessel. The SCD cells traveled through the device at a fixed pressure
and were observed using phase contrast microscopy (Figure 4). Image analysis was used
to quantify the number of cells that adhered to the epithelial layer and their associated
deformability. Over 100 blood samples were analyzed, and the results showed that there
was an identifiable population of RBCs matching an SCD phenotype. The device was
able to classify RBCs as SCD cells based on high deformability and adhesion. This is an
example of a point of care diagnostic device that does not require any complex
processing of blood. It is an assay that relies simply on mechanical properties of RBCs.
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Figure 4. Sickle cell detection on biochip. (A) Flow illustration. (B) RBCs adhered inside
the device. (C and D) High resolution images showing high and low adhesion examples
[19].
Similarly, a study led by Kolluri showed that malaria infected RBCs could be
separated from normal RBCs with a microfluidic device [20]. Malaria is a mosquitoborne disease where RBCs are infected by a parasite. The parasite lives in the host cell
and secretes a substance that abnormally crosslinks the membrane proteins, stiffening the
cell. A unique device design was used to make the malaria infected RBCs undergo
margination. Margination in flow occurs when heavier, rigid objects move to the side of a
channel while more deformable and smaller objects stay close to the center of the
channel. This phenomenon can also be seen in normal RBCs and leukocytes, where the
spherical and less deformable leukocytes are forced against the channel walls. Using this
microfluidic device, malaria infected cells were efficiently isolated from the healthy cells.
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Chronic kidney disease (CKD) can also affect RBC biomechanics, but not as severely
as SCD or malaria. The progressive damage to the kidneys prevents them from being able
to perform normal metabolic activities, and this can be measured in blood. The kidneys
become more prone to oxidative damage, and the cardiovascular system generally
develops complications. Faustino et al. used a converging microchannel design to assess
the RBC deformability of patients with end-stage kidney disease (ESKD), which
develops from CKD and marks the failure of the kidneys [21]. RBC suspensions were
perfused through the microfluidic device and observed at two regions of interest: high
shear constriction and low shear area at the constriction’s exit (Figure 5). The
deformation ratio (DR) was measured for the RBCs at both regions. DR is defined by
LMajor/LMinor, which refer to the major and minor axis lengths of ellipse shaped cell.
Higher DR values indicate more elongation and consequently higher degrees of
deformability of the RBCs.

Figure 5. Microfluidic system for ESKD RBC deformability assessment [21].
Three groups of blood donors were assessed: ESKD, ESKD with diabetes, and
healthy controls. The results showed that RBCs from patients with ESKD elongated 8%
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less than those of the healthy controls. Patients with ESKD and diabetes were even less
deformable, at 14% less elongation than the healthy controls. These measurements were
taken at the constricted region and were statistically significant (p < .05). Interestingly, at
the second region of interest where the shear stresses are lower, the DR measurements
were similar in all three groups. This highlights the importance of applying enough
mechanical stress to a cell to induce shape transitions and uncover abnormalities. Unlike
SCD and malaria where affected RBCs are morphologically discernable under static
conditions, RBCs in ESKD must be exposed to high shear stress in order to observe their
defects. Although these differences in deformability are more subtle, they are measurable
using microfluidics and similar results can be expected in ME/CFS.
2.3 The Effects of CFS on the Cardiovascular System
There have been several studies with aims of finding more objective characteristics
for diagnosing CFS. Extensive research explored the heart rate, blood pressure, and blood
chemistry in patients with CFS.
CFS patients typically show signs of orthostatic intolerance, or symptoms that worsen
in a standing position [22]. The discomfort tends to decrease in a reclining position. Past
research has noted that the cardiovascular system has altered function in some CFS
patients during orthostatic stress. To further explore these findings, researchers recruited
44 patients (19 with suspected CFS and 25 without CFS) and recorded various
cardiovascular characteristics [22]. In this study, measurements for blood pressure, heart
rate, ejection fraction, and biochemical characteristics were taken.
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The CFS patients were found to have significantly lower blood pressure than patients
without CFS, particularly in the diurnal state [22]. The other parameters, including heart
rate and ejection fraction, were similar between the two groups. This suggests that CFS
has an effect on the cardiovascular system that is stronger during the day, or when the
patients are typically more active. It is also consistent with the previous results on
orthostatic intolerance. Low blood pressure may be one of the triggers for the symptoms
of CFS, so it may be worth taking a closer look at the fluid properties of blood and how it
moves through vasculature.
There are key signs of oxidative stress in CFS patients’ plasma, the component of
blood without RBCs. A study by Kennedy et al. investigated the levels of 8-isoprostaglandin-F2α-isoprostanes, a by-product of oxidative stress. In this study, patients
with CFS, exhibited significantly higher isoprostane levels than patients without CFS
[23]. Furthermore, patients with CFS had significantly higher OxLDL (oxidized lowdensity lipoprotein concentrations in plasma (Table 1). OxLDL occurs when low-density
lipoproteins, or cholesterol, react with unstable free radicals. A higher level of OxLDL
indicates there is more damage due to oxidation in the body. Since there is strong
evidence showing the extent of oxidative stress in CFS, RBCs should measurably
experience some of the effects of oxidation.

15

Table 1. Oxidative Stress Markers in Patients with CFS [23]
CFS patient group

CFS patients

Controls

P-value

Subject numbers

n=31

n=30

Sex M:F

14:17

13:17

Age mean (range)

46 years (19-64)

45 years (19-60)

Smoking Y:N:Ex

4:25:2

5:24:2

BMI (kg/m2)

23.9 (3.4)

24.2 (2.8)

0.67

Cholesterol

5.02 (1.1)

5.10 (0.99)

0.77

HDL (mmol/L)

1.31 (0.30)

1.60 (0.46)

0.005

OxLDL (mU/ml)

32.8 (13.8)

30.8 (10.0)

0.02

F2α-isoprostanes

406 (192)

318 (113)

0.03

GSH (µmol/L)

1284 (291)

1372 (240)

0.2

Supine systolic

116 (12)

118 (11)

0.48

70 (10)

71 (10)

0.76

87 (9)

0.59

118 (14)

121 (15)

0.41

71 (12)

75 (10)

0.17

86 (11)

90 (11)

0.2

(mmol/L)

(pg/ml)

pressure (mm Hg)
Supine diastolic
pressure (mm Hg)
Supine mean arterial 85 (9.5)
pressure
Standing systolic
pressure (mm Hg)
Standing diastolic
pressure (mm Hg)
Standing Mean
Arterial Pressure
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Chapter 3: Research Hypothesis and Objectives
3.1 Hypothesis
We hypothesized that the biomechanical properties in RBCs from CFS patients would
be significantly different from those of healthy control subjects. The null hypothesis was
that there will be no significant difference in the biomechanical properties between the
healthy and CFS groups.
To test this hypothesis, we used a microfluidic system capable of single cell analysis
that is more sensitive than high throughput RBC deformability tests in current literature.
We expected a difference in RBC biomechanics based on past studies on oxidative
damage and diminished RBC deformability. Deformability in RBCs was measured using
various metrics involving transit velocity, change in area, length, and circularity.
3.2 Specific Aims
Aim 1: Compare biomechanical properties of untreated and artificially stiffened RBCs.
Aim 1 serves as a method for validating the effectiveness of the microfluidic device
for measuring differences in RBC deformability. Glutaraldehyde was used to treat normal
RBCs, resulting in the crosslinking of structural proteins in the cell. The treated cells
maintained a rigid, stiff discoid shape. When they flow through constrictions in the
microfluidic channels, we expect them to deform minimally and travel through the
channels slowly. The healthy cells formed a parachute shape and travel through the
constriction more easily.
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Aim 2: Compare biomechanical properties of RBCs from patients with CFS and healthy
controls
After validating our experimental setup with artificially stiffened cells in Aim 1, we
tested CFS samples against healthy controls, matched by sex and age.
Aim 3: Make inferences on mechanisms in CFS that cause biomechanical changes
Based on results from Aim 2, we made inferences on the underlying cause of the
biomechanical differences in healthy RBCs and RBCs from patients with CFS. We
planned and conducted assays to evaluate cellular components in greater detail, the
membrane proteins, cytoskeleton, and cytoplasm.
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Chapter 4: Materials and Methods
4.1 Materials
For this work, the materials and equipment required were primarily for microfluidic
device manufacturing. Some reagents were also used during the experiments. These items
are shown in Table 2.
Table 2. Materials and Equipment
Material/Equipment
Name
PBS

Supplier

Specifications

Gibco

1x

F-127

MilliporeSigma

10% Solution

Plasma Cleaner

Harrick Plasma

Model PDC-32G

Sylgard 184 PDMS

Dow Corning

Glass Slides

Fisher Scientific

Patient Blood Samples

Stanford Genome
Technology Center

4.1.1 Microfluidic Device Fabrication
The microfluidic geometries were designed on CAD software (Solidworks). The
designs were etched onto silicon wafers using photolithography. The silicon wafers
(molds for replication) were manufactured by an outsourced company. To create the
microfluidic device with microchannels by soft lithography, polydimethylsiloxane
(PDMS; Dow Corning) was crosslinked and poured over the molds and placed in an oven
(Thermofisher) at 90°C. Assembly of the final device was done by treating the PDMS
and glass slides (Fisher Scientific) with plasma using a plasma cleaner (Harrick Plasma)
and pressing the two parts together to form a permanent bond.

19

4.1.2 Flow Experiment
The flow experiment involved the microfluidic device connected to a vacuum pump.
The system was imaged using a Leica DMi8 microscope on brightfield settings. The
images were captured using a Phantom VEO 410-L highspeed camera (Ametek Inc.).
4.1.3 Image and Statistical Analysis
The raw camera captures were transferred to a computer for image processing. The
image analysis software, ImagePro 10 (Media Cybernetics) was used to extract various
measurements from the captured videos. The raw data were then formatted and used to
create plots with MATLAB (Mathworks).
4.2 Safety
When handling PDMS, proper personal protective equipment (PPE) was used. PDMS
is relatively safe but can cause eye irritation. Safety glasses, chemical resistant gloves,
and appropriate clothing were worn when working with this material.
Phosphate buffered saline is mostly water, with sodium chloride, potassium chloride,
and sodium phosphate. Exposure to the skin, eyes, or respiratory tract may cause
irritation. Splash goggles and gloves were worn when handling PBS. Similar safety
standards were followed for F-127.
Blood-borne diseases are a major risk when preparing samples for the experiment. All
samples were prepared in a biosafety cabinet to ensure the experimenter was not exposed
to the blood. Lab coats and gloves were worn at all times and blood waste was discarded
in a designated waste container.
For each chemical in this experiment, the material safety data sheet was consulted
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before use. The locations of showers and eyewash stations were known to the
experimenter prior to conducting experiments.
4.3. Methods
4.3.1 Microfluidic Device Fabrication
The outer edges of the silicon wafer were wrapped in aluminum foil and placed in a
glass petri dish. PDMS was mixed using a 10:1 ratio of the elastomer base and the
crosslinking agent. The mixture was stored in a 50 mL Falcon Tube and mixed using a
vortex mixer for 30 seconds, then the tube was inverted for 30 seconds. The tube was
mixed and inverted a total of 10 times. The uncapped Falcon Tube was then removed and
placed upright in a vacuum desiccator for approximately 20 minutes (or as needed) to
remove air bubbles from the solution. After the bubbles were removed, the solution was
poured onto the silicon wafer.
The PDMS completely covered the microchannels on the mold and reached a height
of approximately 0.5 inches in the petri dish. The molds filled with PDMS were then
baked in the oven at 90°C for 2 hours to complete the curing process.
After the 2 hours of baking, the molds were removed from the oven and allowed to
cool to room temperature. Then, the areas containing microchannels were excised from
the wafer, to obtain small rectangular PDMS “chips.” To create the inlet and outlet
openings, a biopsy punch was used to create circular holes of 2 mm diameters.
Before bonding the PDMS to a glass slide to assemble the completed device, the
chips were cleaned with ethanol. Both sides were sprayed with ethanol and air dried.
Clear adhesive tape was applied to the surfaces and removed to pull off dust or dirt
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particles. The chips were placed into the plasma cleaner, channel-side up with a glass
slide. Plasma treatment was applied for 3 minutes after which the chips are placed on the
glass slide, channel-side down, forming a permanent bond with the glass. The assembled
device was placed in the oven at 90°C for 2 hours. The device is then ready to be used in
the flow experiment.
4.3.2 Flow Experiment
To perform the flow experiment, a cell suspension must be processed from a whole
blood sample. Whole blood samples were obtained from Stanford Genome Technology
Center in lithium heparin Vacutainer tubes (BD Biosciences). The tubes were centrifuged
at 250 x G for 20 minutes to separate the packed RBCs from the platelet rich plasma
(PRP). In a biosafety cabinet, the top layer of PRP was carefully aspirated out and stored
in small tubes. The middle section between the RBC and PRP layers was removed and
discarded. The RBCs were diluted in the donor’s own plasma and in PBS to a
concentration of 0.5%.
Next, the microfluidic devices were primed. The channels were filled and wetted with
PBS and 0.1x Pluronic F-127. After the channels were free of air bubbles, the outlet of
the chip was connected via silicone tubing to a vacuum pump. The chip was placed in the
field of view of the microscope at 40x magnification where the channels were clearly
visible. Finally, a small volume of the blood sample (10 µL) was pipetted into the inlet of
the chips. The pump was switched on to create a -2 psi pressure, and the flow of cells was
recorded with the high-speed camera at 2000 frames per second. The experimental
workflow is shown in Figure 6, followed by the image analysis step.
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Figure 6. Microfluidic experimental procedure. (A) Primary steps of experiment.
(B) Typical motion of a cell through a channel. Scale bar is 20 µm.
4.3.3 Assessing Alternate Channel Designs
Preliminary research has shown that diminished RBC deformability in patients with
CFS can be measured in long, straight 5 µm constrictions. In the current study, three
other channel designs were assessed for their efficacies in measuring the greatest
difference between healthy RBCs and RBCs from CFS patients. The designs were
labeled according to the dimensions of the four test channels (i.e. width µm x length µm).
All channel heights were 5 µm. The primary design consists of straight channels where
the 5 µm constricted region is 250 µm in length (5 x 250). This length is required for an
RBC transition from an ellipsoid shape to a “parachute” near the end of the channel and
revert towards its original shape as it exits the constriction. In addition to this, 5 x 14

23

channels and 5 x 13 multi-constriction (MC) channels were designed and tested (Figure
7).
The 5 x 14 channels were designed to briefly stress RBCs in a short constriction and
observe the increased acceleration and deceleration, as well as the rapid deformation and
recovery. The 5 x 13 multi-constriction are intended to explore lasting effects of repeated
loading on a cell. The test is similar to fatigue testing of materials.
In addition to these 5 µm constriction designs, 7 µm constrictions were also tested.
They have the same basic geometry (7 x 250 and 7 x 13 MC) with the only difference
being the slightly larger constriction. These channels are used to investigate if RBC
deformability differences can still be seen using less confinement than was used in the
preliminary study.
Other than MC channel designs, the microfluidic devices described here contain
bypass channels. “Bypass” channels in a microfluidic system refer to channels outside of
the test region that are intended to maintain equal pressures across the system. If a test
channel is partially obstructed by RBCs, the large bypass channels mitigate disruptions in
the flow pattern by offering a low-resistance path to relieve pressure buildups.
Preliminary designs that did not have bypass channels were quickly removed from the
study because the pressure differences between the test channels likely contributed to
inconsistent data.
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Figure 7. Channel designs for microfluidic experiments.
4.3.4 Image and Statistical Analysis
ImagePro 10 was used to measure various parameters from the captured images. The
raw video files from the camera were first converted to .avi files using PCC 3.1. Once
they were imported to ImagePro, the pixels of the flowing cells were separated from the
background pixels of the image, and several filters were applied to each frame to enhance
the segmentation of the cells. Each cell was motion tracked, and the data were exported
to an Excel file. Matlab and Prism were used to generate graphical representations of the
data. The main analysis steps are shown in Figure 8.
To determine if any measurements were statistically significant, the values of a
donor’s cells at a point in the channel were averaged and compared to the values from
another donor. After enough patient data were collected, two-tailed paired sample t-tests
were done to evaluate statistical significance.
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Figure 8. Image analysis process and data visualization.
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Chapter 5: Expected Budget and Schedule
The costs for the required materials are shown in Table 3. Table 4 shows the expected
schedule for the work described.
Table 3. Budget
Material/Equipment
Name
PBS

Supplier

Cost

Gibco

$35.10/1000 mL

F-127

Millipore Sigma

$221.00/50 mL

Plasma Cleaner

Harrick Plasma

Available in E203

Sylgard 184 PDMS

Dow Corning

$197.00/5 boxes

Glass Slides

Fisher Scientific

$90.00/ 144 slides

Patient Blood Samples

Stanford Genome
Technology Center

Donated

Table 4. Project Timeline
Task Name

Status

Initial Project Setup

Start Date

End Date

07/01/19

10/11/19

Optimize Microfluidic System

Complete

07/01/19

08/31/19

Develop Automated Software Cell
Tracking

Complete

09/01/19

10/11/19

10/14/19

03/10/20

Conduct Patient Experiments
Microfluidic Experiments

Complete

10/14/19

03/31/20

Data Analysis/Plotting

Complete

11/04/19

03/10/20

03/10/20

05/11/20

Compile Results
Conduct Follow-up Assays

Complete

03/10/20

04/10/20

Write Thesis

Complete

04/13/20

05/11/20
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Chapter 6: Results and Discussion
6.1 Microfluidic Experiment Validation
To validate the microfluidic system’s efficacy in measuring deformability, RBCs
were artificially stiffened and tested in the device. RBCs obtained from healthy
individuals were suspended in 1x PBS and a 1x PBS solution with 0.01% glutaraldehyde.
The RBCs treated with glutaraldehyde were incubated at room temperature for 10
minutes for the stiffening effect to occur. Both RBC suspensions were perfused through
the device where they flowed at -2 psi. The experiment was performed for 3 donors (n=3)
and approximately 100 cells were analyzed from each pair. Representative data are
shown in Figure 9.
The RBCs stiffened by glutaraldehyde traveled through the channels at lower
velocities than the untreated RBCs. In Figure 9C, the average velocities of all cells in the
experiment are plotted against their positions (x-coordinates) through the channels. The
vertical black lines represent boundaries of the 5 µm constriction. The glutaraldehyde
treated cells seem to resist changing shape as they become confined, causing them to
flow through the channels much more slowly than untreated cells. In the population of
cells for the 3 donors (n=3), the untreated cells had significantly lower mean peak
velocities through the constrictions (untreated 43328 ± 417.7 µm/s , N=363,
glutaraldehyde 34049 ± 768.5 µm/s, N=281, (p<0.0001).
Circularity is used as a measure of how closely an object resembles a circle, where a
shape with a value of one would be a perfect circle and values approaching 0 would be
more ellipsoid. This measurement is shown in Eq.1. Figure 9D shows the circularity of
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the RBCs about 20 µm before entering the constriction. In RBCs treated with
glutaraldehyde, the values in the distribution generally approach 1 while the untreated
cells average ~0.5 (untreated: .53 ± .122, glutaraldehyde .72 ± 0.02).

Figure 9. Untreated vs. glutaraldehyde microfluidic data, scale bar is 20 µm.
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Finally, we calculated the area deformation indices (ADI) (Figure 9E). This
measurement is the ratio of a cell’s projected area while it is inside the constriction to the
projected area before it enters the constriction. Untreated RBCs elongate in the
constriction and that contributes to increased projected areas compared to its initial areas.
The glutaraldehyde treated RBCs get compressed but do not elongate as much, so their
ADIs are typically lower (untreated 0.9 ± .26, glutaraldehyde 0.66 ± 0.05). The
differences in circularity and ADI did not attain statistical significance at n=3; however
both measurements were markedly higher in glutaraldehyde with a ~30% difference.
The results from these experiments show that the microfluidic system is able to detect
differences between the two conditions. From the results we can infer that the
glutaraldehyde treated RBCs are more resistant to deformation than untreated RBCs. In
patients with CFS we do not expect to see morphological changes as striking as we see
here. However, the microfluidic system should be sensitive enough to show statistically
significant results in our diverse set of measurements and channel designs.
6.2 RBC Flow Experiments with CFS Patients
After validating the capabilities of the microfluidic device and the image analysis
software, experiments were conducted with CFS patients. Whole blood samples were
obtained from patients with CFS and healthy controls (HC) matched by sex and age. In
the initial stages of the patient trials, there were several different experimental treatments
and conditions to determine the most effective method for biomarker discovery. The test
conditions involved a combination of solutions to resuspend the RBCs and various
channel designs previously described in Section 4.3.3. (Table 6).
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Table 5. Experimental Conditions
RBC Suspension Solution

Channel Design

Own plasma

5 x 250

Phosphate buffered saline (PBS)

5 x 13 MC

Swapped plasma

5 x 14

Whole blood

7 x 13
7 x 250

6.2.1 Evaluation of RBC Suspension Mediums
As the patient experiments progressed, the conditions that were less effective were
omitted. This allowed us to perform more replicates of conditions that we are more
confident about. For the “own plasma” condition, isolated RBCs were diluted in the
donor’s own plasma. Similarly, PBS was used to form another condition. PBS was
chosen as a way to remove plasma proteins that may affect RBC deformability.
Experiments with cells in PBS were expected to produce measurements purely based on
the mechanical properties of the cell, with minimal external influences. Whole blood
samples were also prepared. Whole blood was diluted in PBS, without any centrifugation
or separation of RBCs. The aim of this was to eliminate time-consuming centrifugation
from the process, speeding up the experiment. Since the fraction of cells other than RBCs
in whole blood is negligible, we expected results similar to those of pure RBCs. To
explore the effects of plasma on RBCs, we tried using plasma from one donor to dilute
RBCs from another. However, the swapped plasma experiments were quickly deemed
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unfeasible since blood types of the pairs must be matched to avoid agglutination, or the
clumping of cells. Blood type data from patients were unavailable to us for this study.
The experiments using PBS suspensions showed inconsistent results between most
donors. Microscopic images also showed that the normal morphologies of the cells were
sometimes altered after short incubation periods in PBS. The biomechanics of PBS
treated cells may not be reliable to use for measurements for diagnostic purposes. A
similar conclusion was made for the whole blood experiments, which also used PBS.
6.2.2 Evaluation of Channel Designs for CFS Samples
Representative velocity data for one donor pair are shown below (Figure 10). The
most consistent results were seen using the 5 x 250 design with the donor’s own plasma.
The channels with 7 µm constrictions (7 x 250 and 7 x 13 MC) did not always show
trends matching those of 5 x 250. Differences in velocity between CFS and HC were not
as reproducible as in the 5 x 250 design; this could be due to insufficient confinement of
the cells in the constrictions. The channel with a 14 µm length (5 x 14) showed some
differentiation in cell velocity, but morphological changes were difficult to observe. At
our chosen framerate, the cells were only imaged inside the constriction for one or two
frames because of their high velocities. Parameters like area, circularity, and length could
not be measured accurately so these channel designs were discontinued. The majority of
the CFS patient experiments were carried out with 5 x 250 as the most effective design.
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Figure 10. CFS/HC velocity curves of all channel designs.
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6.3 CFS Experimental Data
The dataset for 5 x 250 with the donor’s own plasma is made up of 16 matched pairs
(n=16). Out of the four base parameters that were measured, the differences were found
in the velocities through the channels. All the measured parameters and data are shown in
Table 6.
Table 6. Microfluidic deformability parameters for HC and CFS samples
HC

CFS

PValue

Initial Area (µm2)

49.18 ± 8.37

51.77 ± 7.81

Ns

Transit Area

51.21 ± 9.36

51.51 ± 8.72

Ns

Exit Area (µm2)

50.67 ± 7.38

52.76 ± 7.22

Ns

Initial Velocity

8950.52 ± 1282.92

8311.30 ± 1031.41

Ns

25351.52 ± 2410.061

22868.45 ± 1724.89

.0003

11269.74 ± 1812.012

9724.77 ± 1550.48

.008

10.85 ± 0.63

11.14± 0.84

Ns

(µm2)

(µm/s)
Transit Velocity
(µm/s)
Exit Velocity
(µm/s)
Initial Length
(µm)
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Transit Length

13.450 ± 0.68

13.68 ± 0.98

Ns

Exit Length (µm)

11.58 ± 0.70

11.79 ± 0.97

Ns

Initial Circularity

0.58 ± 0.074

0.58 ± 0.058

Ns

Transit

0.39 ± 0.053

0.38 ± 0.058

Ns

0.48 ± 0.048

0.49 ± 0.044

Ns

(µm)

Circularity
Exit Circularity

6.3.1 Measurement of Transit Velocities
The average peak velocities of the cells, measured near the middle of the constricted
region, were significantly higher in the HC group than CFS (Figure 12). Figure 11 shows
a representative instantaneous velocity curve of a paired sample. In this curve, the
velocities between the pairs are closer to each other before they enter the constriction,
and after they exit. The major separation occurs inside the constriction, where the cells
must deform and elongate to flow through. The cells from the CFS donor in this figure do
not reach the same maximum velocity, and this could be attributed to poor deformability
and increased rigidity. In both unpaired and paired t-tests, the mean values attained
statistical significance (n=16, paired p=0.0003, unpaired p=0.0022. HC 25352 ± 2410.6
µm/s, CFS 22868 ± 1724.9 µm/s). It is worth noting that the velocities of both CFS and
HC are similar prior to entering the constriction. This suggests that the RBCs in patients
with CFS are able to flow normally when they are unconfined, but their movement is
impaired under confinement. The differences in velocities first occur inside the
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constriction, and this trend continues until after the cells exit the constriction (p=.008, HC
11269.74 ± 1812 µm/s, CFS 9724.77 ± 1550.48 µm/s).

Figure 11. Representative plot of instantaneous velocities (HC vs. CFS).
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Figure 12. Mean transit velocity in constriction (HC vs. CFS).
6.3.2 Measurement of RBC Projected Areas
Velocity differences were observed in the constricted region of the channel, where the
dcells are expected to be moving the fastest and experience the highest shear rate. The 5 x
250 channel design allows the cell’s exit from the constriction to be observed as well.
This is an improvement over the previous study, where only the cell’s entry into the
constriction could be observed in the microscope’s field of view [16]. As a cell exits the
channel, it slows down and gradually recovers to its normal disc shape. The projected
areas of cells as they exit the constriction were measured to identify trends similar to
those of the glutaraldehyde trials. For n=16 pairs, the average areas of cells as soon as
they exit the channel are shown in Figure 13.
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Figure 13. Projected area at exit (outliers marked).
The average areas in CFS appear to be higher than HC, but this difference did not
attain statistical significance in a paired t-test. However, after removing one outlying pair
(identified in the Figure 13), the difference was significant (n=15, p=0.0273, HC 50.7 ±
1.973 µm2, CFS 53.69 ± 1.653 µm2). RBCs from patients with CFS rapidly expand to
recover to their original shape sooner than those of HC donors. These cells exhibit
properties that are associated with rigid materials with higher elastic moduli. The HC
RBCs probably take more time to reach this projected area since they will remain in
smaller parachute shapes until they have traveled further downstream. Likewise, in the
same adjusted dataset, the initial areas before entering the constriction were significantly
different (p=.04, HC 49.29 ± 8.65 µm2, CFS 52.81 ± 6.83 µm2. Even under low shear, the
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HC RBCs may be deforming and folding more than RBCs in CFS, resulting in a smaller
two-dimensional appearance.
Since we are just taking single measurements at the entry and exit, it may be possible
that the stationary RBCs in CFS are simply larger than HC RBCs. To address this, the
Area Deformation Index (ADI) at exit was calculated. The change in area was
standardized by comparing the cell’s area at exit to the cell’s area in the constriction,
similar to the ADI measurements done in the glutaraldehyde experiments (Figure 14).

\Figure

14. Area deformation index (area at exit/area in constriction) of HC and
CFS cell populations.

The ADI was also plotted for the pooled cell values in all 16 pairs. The histogram of
the combined measurements is shown in Figure 14, with approximately N=8000 cells in
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each group (HC 1.012 ± 0.12, CFS 1.038 ± 0.14) Although there is substantial overlap
between the two distributions, the right-hand tail of the CFS distribution reaches greater
ADI values than the HC’s. This is evident from the 75th percentile values, where HC is
1.09 and CFS is 1.13. The distinction is not as pronounced as it was with glutaraldehyde,
but it is clear that the CFS population has signs of reduced deformability.
6.3.3 RBC Biomechanics and CFS Severity
Relating the symptoms of a disease to a potential biomarker is a key step in
developing a diagnostic test. Ideally, the severity of CFS patient’s symptoms should be
associated with his or her RBC deformability measurements. In CFS, severity of
symptoms is rated using the Bell disability scale which is self-scored by the patients [24].
The Bell scores range from 0-100 and the symptoms presented for each score are
described below.
Bell Disability Scale
100: No symptoms at rest; no symptoms with exercise; normal overall activity level; able
to work full-time without difficulty.
90: No symptoms at rest; mild symptoms with activity; normal overall activity level; able
to work full-time without difficulty.
80: Mild symptoms at rest; symptoms worsened by exertion; minimal activity restriction
noted for activities requiring exertion only; able to work full-time with difficulty in jobs
requiring exertion.
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70: Mild symptoms at rest; some daily activity limitation clearly noted. Overall
functioning close to 90% of expected except for activities requiring exertion. Able to
work full-time with difficulty.
60: Mild to moderate symptoms at rest; daily activity limitation clearly noted. Overall
functioning 70%-90%. Unable to work full-time in jobs requiring physical labor, but able
to work full-time in light activity if hours flexible.
50: Moderate symptoms at rest. Moderate to severe symptoms with exercise or activity;
overall activity level reduced to 70% of expected. Unable to perform strenuous duties,
but able to perform light duty or desk work 4-5 hours a day, but requires rest periods.
40: Moderate symptoms at rest. Moderate to severe symptoms with exercise or activity;
overall activity level reduced to 50%-70% of expected. Not confined to house. Unable to
perform strenuous duties; able to perform light duty or desk work 3-4 hours a day, but
requires rest periods.
30: Moderate to severe symptoms at rest. Severe symptoms with any exercise; overall
activity level reduced to 50% of expected. Usually confined to house. Unable to perform
any strenuous tasks. Able to perform desk work 2-3 hours a day, but requires rest periods.
20: Moderate to severe symptoms at rest. Unable to perform strenuous activity; overall
activity 30%-50% of expected. Unable to leave house except rarely; confined to bed most
of day; unable to concentrate for more than 1 hour a day.
10: Severe symptoms at rest; bedridden the majority of the time. No travel outside of the
house. Marked cognitive symptoms preventing concentration.
0: Severe symptoms on a continuous basis; bedridden constantly; unable to care for self.
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Most CFS patients in this study have Bell scores between 0-50, or severe to moderate.
Some patients with scores above 70 can be fully functional individuals in society but
have mild symptoms.
Focusing on constriction velocity, we then calculated the percentage of values in an
RBC sample that occurred below a certain threshold point in the CFS group. In this case,
the threshold was set at 22000 µm/s. This value was based on the mean constriction
velocity in the population of CFS patients. A patient with a higher percentage of RBCs
below this threshold should have more severe symptoms, based on our hypothesis. Figure
15 shows a scatter plot of the Bell scores versus the “low velocity RBC frequency,”
which is defined as the percentage of cells in each patient sample that do not exceed a
velocity 22000 um/s.

Figure 15. Bell score vs. low velocity RBCs.
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The dataset here only shows CFS patients, without their corresponding HC matches
(n=18). Since this is not a paired analysis, we were able to add additional CFS points
from experiments that had abnormal or outlying HC measurements. The majority of
normal CFS patients shown have low velocity RBC frequencies in the range 20-60. The
Bell scores for this cluster are generally 0-50. Further along the x-axis at 70, there is one
patient with mild symptoms. The low velocity RBC frequency % for this patient is under
20, which is lower than any other patient in the normal CFS cluster. The clinical
implications of analyzing the data this way could serve as precursors to a diagnostic test.
Based on this population, we can say that if a donor has more than 20% of their RBCs in
the low velocity range, he or she has a higher probability of experiencing more severe
CFS symptoms. Combining these data with other supplemental assays can lead to
determining a critical point where a diagnosis can be more certain. We can see that there
is almost a linear relationship (R2 = .4325) between the x and y axes, showing that a
larger fraction of low velocity RBCs is associated with a higher Bell score. This may
seem counter-intuitive because as this frequency increases, the severity of symptoms
decreases. One explanation is that the symptoms are caused by the body’s response to
stiffer RBCs in CFS (i.e. vasodilation, oxygenation) and we cannot observe this in our in
vitro capillary model. However, this association tells us that we need a more advanced in
vitro model in the future to explore key dynamic physiological parameters that may be
affecting symptoms.
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Additionally, the fraction of low velocity RBCs from each CFS patient was compared
to that of the HC donors to calculate a ratio (Figure 16). This reduces any variability that
could have been present in day to day experiments.

Figure 16. Bell score vs. low velocity RBC ratio.
In this plot (n=15, excluding a patient with a missing Bell score), there is less of a
linear correlation (R2 = .3875) but the points seem to be clustered near the y=1 line
(dashed line). At lower Bell scores, there seem to be less differences between the CFS
and HC velocity distributions (1:1 ratio). As the symptoms become less severe, it
becomes easier to discriminate between CFS and HC. Again, this warrants the need for a
more physiologically relevant model to determine how symptoms relate to RBC
biomechanics.
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6.3.4 Improvement of CFS Symptoms Following CCI Surgery
One exceptional patient, not included in the above analyses, underwent
Craniocervical Instability (CCI) treatment surgery. CCI is a condition that can cause
compression on the spinal cord and/or brainstem area due to abnormal alignment of
bones in the craniocervical junction. CCI has some anecdotal association with the
symptoms of CFS, and patients who were diagnosed with both conditions have reported a
reduction in symptoms following the surgery [25]. We received a sample from one
patient who had CFS but became asymptomatic and recovered completely after getting
treated for CCI. Based on the description of the patient post-surgery, we assumed he or
she should be given a Bell score of 100. Interestingly, the results showed that the RBC
velocity from that patient matched the healthy control almost perfectly (Figure 17). This
shows there may be a correlation between a lack of symptoms and “normal” RBC
velocity measurements, although this is a limited sample of only one patient.
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Figure 17. Recovered patient RBC velocity.
6.3.5 SS-31 Antioxidant Drug Experiment
In another special case, we tested the effect of an antioxidant drug called SS-31 on
RBCs. SS-31 helps restore redox homeostasis to reduce oxidative damage. In mice, SS31 treatment was shown to reverse muscle tissue damage caused by oxidation [26]. It is a
novel drug, so literature on its effects specifically on RBCs is sparse. However, this study
has shown that SS-31 increased the free reduced glutathione (GSH) in muscle cells and
restored the membrane structure in damaged mitochondria. Since RBCs in patients with
CFS have similar oxidation-related deficits, we can speculate that SS-31 will have a
therapeutic effect on patients with CFS. Because of limited access to the drug, we could
only perform one experiment using our microfluidic system with a CFS patient sample.
The blood was treated with 10 ng/mL SS-31 and incubated it for an hour at 37 °C.
One of our calculated measurement types, called the elongation index is shown below for

46

the SS-31 experiment on the 5 x 13 MC channel design (Figure 18). Elongation index is
similar to ADI but uses the major axis length rather than area as the denominator in the
ratio. It is a measure of how much a cell elongates in a single direction, which is expected
to be the direction of the flow. The CFS cells treated with SS-31 seem to have elongation
indices that match with those of the HC curve. This difference was only observed in 5-13
MC and shows the potential of cyclic loading to elicit a biomechanical response from a
cell.

Figure 18. SS-31 trial on 5-13 MC.
6.4 Other Hematologic Assays
Data produced by the microfluidic system confirmed that RBC deformability is
reduced in CFS. The next phase, as per Aim 3, was to conduct other assays or tests to
understand how and why RBC mechanical properties are altered.
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6.4.1 Hematocrit Measurement
The first and most simple test that was added to the experimental protocol was a
hematocrit count. The hematocrit, or fraction of RBCs in whole blood, directly influences
blood rheology and may play a role in the symptoms of CFS. Hematocrit was measured
using capillary tubes in duplicates for each donor. The results to date show that CFS
patients tend to have lower hematocrit counts than healthy donors. Figure 19 below
shows a box and whisker plot for 10 pairs (n=10).

Figure 19. Hematocrit HC vs. CFS.
6.4.2 Osmotic Fragility
In addition to measuring hematocrit, we began trial experiments for osmotic fragility
of RBCs. RBC stiffness can be affected by cytoplasmic viscosity, membrane proteins,
and other factors. An osmotic fragility assay measures the membrane’s ability to remain
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structurally sound when stress is applied. As an RBC ages during its normal lifespan, it
develops microdefects in the membrane and becomes more fragile [27]. Since osmotic
fragility is associated with reduced deformability, performing these experiments in
parallel with microfluidic experiments may help explain why CFS cells are stiffer.
An osmotic fragility assay involves suspended RBCs in hypotonic solutions of
increasing NaCl concentrations, from 0-0.9% (isotonic). The membranes fail at hypotonic
levels and the cells rupture, releasing hemoglobin into the solution. The free hemoglobin
is directly proportional to cell lysis and can be measured with spectroscopy. The resulting
curve can be a good indicator of cell membrane fragility. The current protocol is still
being optimized and improved, but a few experiments with patients were performed
successfully.

Figure 20. Osmotic fragility curves (CFS/HC), 6 and 10 data points.
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In Figure 20, the osmotic fragility curves for two pairs of donors is shown. The plot
on the left was done with six concentrations of NaCl, 0-0.9% in increments of 0.2%.
There did not appear to be major differences, and the curve seemed to lack detail. To
address this, the next experiment on a different pair of donors was done with 10
concentrations, with increments of 0.1. The new curve shown on the right offered more
information than the initial one; however, there were no major discernable shifts in the
curves between HC and CFS. More samples are necessary before we can draw
conclusions.
A study compared the osmotic fragility curves of normal RBCs and ozone treated
RBCs to measure the effects of oxidative damage on the cell membranes [28].
Abnormally fragile RBCs tend to have osmotic fragility curves that are shifted to the
right, indicating greater hemolysis (Figure 21). We hypothesize seeing a similar trend in
RBCs from patients with CFS as these experiments progress in the future.

Figure 21. Osmotic fragility curves, untreated and ozone [28].
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Chapter 7: Conclusion
7.1 Conclusion
Several conclusions are evident based on the results of this study:
•

RBCs in patients with ME/CFS have altered biomechanical properties that may
play a role in the symptoms or origins of the disease.

•

Microfluidic experiments show that RBC deformability is reduced in patients with
ME/CFS.

•

RBCs in patients with ME/CFS travel through constrictions more slowly and are
more resistant to shape changes than healthy RBCs.

•

Advantages over the preliminary study include greater accuracy of measurements,
5-8x higher throughput of measurable cells, and automated image analysis for
cytometry.

•

The automated image analysis is a stand-alone protocol that can be applied to
other microfluidic based cell biomechanics studies.

7.2 Future Work
The work presented has several advantages over the past preliminary study [16]. The
results are consistent in both studies. To move closer to a diagnostic test for CFS, we
need to collect more data on the individual patients. RBC biomechanical properties can
be highly sensitive metrics, and there are many other factors that can influence them.
Plasma components like glucose and proteins affect RBC deformability. Medications and
other health conditions may also play a role in blood rheology. For deformability itself to
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be considered a biomarker for CFS, as many of these external factors as possible should
be controlled for.
One factor that affects the deformability of blood is the partial pressure of oxygen gas
in blood (PO2). Zhou et al. showed that by varying PO2, RBC capillary velocity and
deformability can be modulated [29]. By controlling oxygen in our future experiments,
we will develop a system that is more physiologically relevant and may produce more
meaningful data.
The state of the donor at the time of the draw may also be important. CFS patients can
“crash” or experience severe post-exertional malaise. RBCs may behave differently if
they are drawn during one of these events. This may have been observed by Simpson in
the 1990s, who reported that patients “exposed to a stressful situation will have shapechanged red cells” [30]. The “stressful events” may refer to the crashes, and, as Simpson
also noted, RBC morphology can vary on a minute to minute basis.
CFS is a disease that has puzzled scientists and doctors for years, and this work
describes a promising area of interest to explore. RBC biomechanics are information-rich
and can affect macrophysiology significantly. Learning more about the biomechanical
properties of RBCs and their interactions with the body may help shed light on the
mechanisms of this strange disease.
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